FDA Approves Ocrevus Zunovo™ First Twice-a-Year 10-Minute MS Injection
Genentech, part of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating both relapsing multiple sclerosis (RMS)…
Dupixent Approved in U.S. as First Treatment for Adolescent CRSwN
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) as an add-on maintenance therapy for adolescents…
Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19…
Enhertu Shows Strong Efficacy in HER2-Positive Breast Cancer with Brain Metastases
Results from the DESTINY-Breast12 Phase IIIb/IV trial reveal that Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, including those with brain…
FDA Approves Roche’s Tecentriq Hybreza First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first subcutaneous (SC) PD-(L)1 inhibitor for cancer…
FDA Approves EBGLYSS™ for Moderate-to-Severe Atopic Dermatitis in Ages 12+
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved EBGLYSS™ (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis (eczema) in adults…
Advancing the Development of Next-Generation Cancer Therapies
Jackson Egen discovered the significance of fundamental lab research during his graduate studies at UC Berkeley in the 1990s, working under the guidance of esteemed immunologist James Allison. “Jim emphasized…
Sanofi, RadioMedix, and Orano Med Sign Licensing Deal for Radioligand Cancer Therapy
Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a U.S.-based biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT), and Orano Med, a French…
Pfizer Showcases Broad Oncology Portfolio and Combination Therapies at ESMO 2024
Pfizer Inc. (NYSE: PFE) continues to highlight groundbreaking research and next-generation therapies from its comprehensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, held from September…
Allergan Aesthetics Launches BOTOX Cosmetic for Masseter Muscle Prominence in Adults in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that BOTOX® Cosmetic (onabotulinumtoxinA) is now available in China for the treatment of masseter muscle prominence (MMP). The masseter muscle,…
Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction to Daily Insulin in Adults with Type 1 Diabetes
Eli Lilly and Company (NYSE: LLY) today released detailed findings from the QWINT-5 phase 3 trial, which compared once-weekly insulin efsitora alfa (efsitora) to daily insulin degludec in adults with…
Oisín Biotechnologies Unveils Preclinical Data from Muscle Building Gene Therapy Program in Cell
Oisín Biotechnologies, a privately held company dedicated to addressing age-related diseases, has announced the publication of preclinical data from its follistatin (FST) gene therapy program. The findings, detailed in the…